Clinical trials
catalyst calendar across sponsors →Studies where DSGN is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
5 interventional
Held by 11 tracked-famous managers (Point72 Asset Management, L.P., Qube Research & Technologies Ltd, RENAISSANCE TECHNOLOGIES LLC, D. E. Shaw & Co., Inc., MILLENNIUM MANAGEMENT LLC, +6 more) · FINRA short interest 12.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's AtaxiaNCT06874010Frequency of treatment-emergent adverse events (TEAE)Open-label · Treatment | Phase 1/2 | Recruiting | Drug: DT-216P2 | Friedreich Ataxia | 20 | Dec 2026 | ≤ 133 d | 2025-05-18 |
| DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal DystrophyNCT07024693FECD Biomarkers: Splicing PanelOpen-label · Treatment | Phase 2 | Recruiting | Drug: DT-168 | Fuchs Endothelial Corneal Dystrophy, Fuchs | 28 | Sep 2026 | ≤ 41 d | 2025-12-29 |
| A Single Ascending Dose Study of DT-216P2 in Normal Healthy ParticipantsNCT06772870Frequency of treatment emergent adverse events (TEAEs)Randomized · Double-masked · Treatment | Phase 1 | Not yet recruiting | Drug: DT-216P2, Saline | Friedreich Ataxia | 36 | Sep 2025 | — | 2025-02-21 |
| Study to Evaluate Multiple Ascending Dose and Multi-Dose of DT-216 in Adult Patients With Friedreich AtaxiaNCT05573698Safety MeasureRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: DT-216, Placebo | Friedreich Ataxia | 32 | 2023-08-25actual | — | 2024-02-29 |
| Study to Evaluate DT-216 in Adult Patients With Friedreich AtaxiaNCT05285540Frequency of treatment adverse events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: DT-216, DT-216 matching Placebo | Friedreich Ataxia | 39 | 2022-12-19actual | — | 2023-03-28 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19